ChAdOx1 MERS vaccine (also known as VTP 500), a vaccine against Middle East respiratory syndrome (MERS) Coronavirus (MERS-CoV), is being developed by Vaccitech (a spin-out company of the University of Oxford) for the treatment of MERS infections. Vaccitech has in-licensed the ChAdOx1 MERS vaccine from the Jenner Institute, University of Oxford. Clinical development is underway in the UK and Saudi Arabia.
In September 2018, University of Oxford and Vaccitech (spun-out from University of Oxford) entered into a licensing agreement for Middle East respiratory syndrome coronavirus (MERS) vaccine. Under the terms of agreement Vaccitech granted certain rights for this vaccine to Oxford for its development for non-profit public-health use. 
In September 2018, Janssen Vaccines & Prevention BV entered into a research and development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Jenner Institute at the University of Oxford, to develop and manufacture a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections. Under the terms of the agreement, Janssen will provide its expertise and technology for vaccines development to advance vaccines against the Lassa and Nipah viruses. CEPI will provide $US14.6 million to Janssen and the Jenner Institute for the ongoing clinical development of adenovirus-vectored MERS-CoV vaccine, ChAdOx1, through phase I studies and manufacturing of clinical trial supplies. CEPI will have the option to provide additional funding for phase II development and manufacturing of an investigational vaccine stockpile available for use in the event of a MERS outbreak, based on the phase I study results. Janssen's proprietary PER.C6® vaccine manufacturing platform will be used for manufacturing for multiple types of vaccines and the creation of this stockpile. CEPI will provide an additional $US4.1 million to fund early-stage, preclinical development of candidate vaccines for the Lassa and Nipah viruses. 
Key Development Milestones
In December 2019, Jenner Institute and the King Abdullah International Medical Research Center (KAIMRC) initiated a phase I trial to assess the immunogenicity and safety of Middle East respiratory syndrome coronavirus vaccine in healthy volunteers in Saudi Arabia   .
In March 2018, Vaccitech initiated a phase I trial to assess the immunogenicity and safety of MERS vaccine in healthy volunteers (MERS001; NCT03399578). The open label trial is enrolling 24 participants in United Kingdom  .
ChAdOx1 MERS vaccine has showed its capacity of inducing antibodies to a level which are protective in animal models.
In December 2018, Vaccitech received £6 million investment from GeneMatrix and Korea Investment Partners and plans to use the investment to advance ongoing clinical projects and expand its research and development  .
In September 2018, The Coalition for Epidemic Preparedness Innovations (CEPI) awarded $US14.6 million to Oxford and Janssen to support manufacturing of a phase II batch and prepare for stockpiling of a MERS-CoV vaccine candidate  .
In January 2018, Vaccitech secured £20 million ($US27.1 million) in Series A financing, and plans to use the funding to expand its business, and to progress its influenza and prostate cancer programmes through phase II by the end of 2019, and advance three other research programmes into clinical development  .